ABBV vs JNJ Stock Comparison: AI Score, Valuation, Performance and Upside
ABBV and JNJ are both large-cap pharma Dividend Aristocrats/Kings facing significant patent cliffs (Humira for AbbVie, Stelara for J&J) while executing next-generation growth strategies. AbbVie's entire identity is Skyrizi and Rinvoq replacing Humira's $20B peak revenue. J&J's diversification across pharma and medical devices provides more resilience. AbbVie's 4% dividend yield is higher than J&J's. Both are quality healthcare income investments with different execution risk profiles.
ABBV vs JNJ — AbbVie (the immunology-focused pharmaceutical company replacing Humira's $20B peak revenue with Skyrizi and Rinvoq immunology drugs while leveraging Allergan's Botox franchise) versus Johnson & Johnson (the pharma + medical device Dividend King with Darzalex oncology dominance, DePuy Synthes orthopedics, and 60+ consecutive years of dividend growth).
ABBV holds the edge across 4 of 5 key metrics in this comparison. JNJ has delivered stronger 1-year price return (+42.90% vs +34.93%), though ABBV has the better forward P/E setup (15.79x vs 21.78x for JNJ). ABBV leads on both revenue growth (10.20%) and operating margin (40.03%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ABBV (+7.85%) than for JNJ (+1.66%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- believe Skyrizi and Rinvoq will collectively exceed Humira's $20B peak sales — if immunology market expansion materializes, AbbVie's revenue story is exceptionally positive despite the Humira cliff
- value AbbVie's 4% dividend yield as the highest among major pharmaceutical Dividend Aristocrats — income investors seeking pharma yield prefer AbbVie's above-sector yield
- see Botox as a unique diversification asset — the aesthetics market is resilient and the therapeutic neurotoxin portfolio (migraine, overactive bladder) creates a non-immunology growth vector
- are comfortable with Humira biosimilar revenue decline, Allergan acquisition debt, and Rinvoq JAK inhibitor safety label risk
- want the most diversified large healthcare company combining pharma (Darzalex, oncology) and medical devices (orthopedics, cardiac) for broader portfolio risk distribution
- value J&J's Dividend King status (60+ years) as the most iconic healthcare income track record with the longest consecutive growth streak among healthcare majors
- see Darzalex's $10B+ peak sales potential and ongoing label expansion as a durable multi-year oncology revenue contributor
- are comfortable with Stelara biosimilar revenue decline, talc litigation financial uncertainty, and Tremfya competing in an immunology market where AbbVie's Skyrizi is currently outpacing J&J
| Metric | ABBV | JNJ |
|---|---|---|
| AI scorei | 63.2 | 50.3 |
| AI ranki | #178 | #500 |
| Latest closei | $286.00 | $266.17 |
| 1M returni | +8.82% | +3.96% |
| 3M returni | +17.31% | +4.41% |
| 6M returni | +38.76% | +18.01% |
| 1Y returni | +34.93% | +42.90% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABBV | JNJ |
|---|---|---|
| 1Y ago | $13.25K (+32.5%) started 2025-11-04 | $14.24K (+42.4%) started 2025-11-04 |
| 5Y ago | $32.13K (+221.3%) started 2021-11-04 | $19.91K (+99.1%) started 2021-11-04 |
| 10Y ago | $113.09K (+1030.9%) started 2016-11-04 | $37.97K (+279.7%) started 2016-11-04 |
Hypothetical — past performance does not guarantee future results.
| Metric | ABBV | JNJ |
|---|---|---|
| Market capi | $454.36B | $645.95B |
| Trailing P/Ei | 72.43 | 31.06 |
| Forward P/Ei | 15.79 | 21.78 |
| Price/Salesi | 5.85 | 4.18 |
| EV/Revenuei | 8.06 | 6.88 |
| Analyst targeti | $277.31 | $272.50 |
| Target upsidei | +7.85% | +1.66% |
| Metric | ABBV | JNJ |
|---|---|---|
| Revenue growthi | 10.20% | 6.60% |
| Earnings growthi | 290.40% | -0.90% |
| EPS growthi | +290.40% | -0.90% |
| FCF margini | +26.20% | +17.24% |
| Operating margini | 40.03% | 29.19% |
| Profit margini | 9.80% | 21.48% |
| ROIC proxyi | 6225.00% | 25.74% |
| Return on equityi | 6225.00% | 25.74% |
| Dividend yieldi | 2.69% | 2.00% |
| Payout ratioi | 190.40% | 80.12% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.28 | 0.23 |
| Debt/equityi | 4789.60 | 57.71 |
| Current ratioi | 0.81 | 1.09 |
| Quick ratioi | 0.49 | 0.72 |
Over the past year, ABBV and JNJ have moved moderately in the same direction (correlation of 0.52), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ABBV | JNJ |
|---|---|---|---|
| 1Y | Growthi | +32.47% | +42.44% |
| CAGRi | +32.55% | +42.55% | |
| Volatilityi | 25.38% | 21.01% | |
| Sharpe ratioi | 1.08 | 1.60 | |
| Sortino ratioi | 1.67 | 2.41 | |
| Max drawdowni | 16.46% | 10.96% | |
| Current drawdowni | 1.65% | 4.40% | |
| Avg drawdowni | 5.05% | 3.51% | |
| Ulcer Indexi | 6.61% | 4.63% | |
| Max daily dropi | 5.20% | 5.73% | |
| Max wkly dropi | 8.49% | 6.99% | |
| 5Y | Growthi | +178.88% | +78.98% |
| CAGRi | +22.77% | +12.35% | |
| Volatilityi | 23.39% | 18.04% | |
| Sharpe ratioi | 0.81 | 0.49 | |
| Sortino ratioi | 1.13 | 0.71 | |
| Max drawdowni | 21.92% | 18.41% | |
| Current drawdowni | 1.65% | 4.40% | |
| Avg drawdowni | 8.03% | 7.12% | |
| Ulcer Indexi | 9.98% | 8.63% | |
| Max daily dropi | 12.57% | 7.59% | |
| Max wkly dropi | 17.30% | 9.18% | |
| 10Y | Growthi | +633.04% | +192.13% |
| CAGRi | +22.05% | +11.32% | |
| Volatilityi | 25.96% | 19.04% | |
| Sharpe ratioi | 0.73 | 0.42 | |
| Sortino ratioi | 1.02 | 0.60 | |
| Max drawdowni | 45.09% | 27.37% | |
| Current drawdowni | 1.65% | 4.40% | |
| Avg drawdowni | 11.47% | 6.45% | |
| Ulcer Indexi | 15.56% | 8.00% | |
| Max daily dropi | 16.25% | 10.04% | |
| Max wkly dropi | 19.39% | 13.25% |
| Category | ABBV | JNJ |
|---|---|---|
| Company | AbbVie Inc. | Johnson & Johnson |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | AbbVie (spun from Abbott in 2013) is the world's leading immunology company famous for Humira — the world's best-selling drug for 10 consecutive years treating rheumatoid arthritis, psoriasis, and Crohn's disease. Humira's US patents expired in 2023, creating a significant revenue cliff. AbbVie's next-generation immunology drugs Skyrizi (interleukin-23 inhibitor) and Rinvoq (JAK inhibitor) are the company's primary growth pillars replacing Humira revenue. AbbVie acquired Allergan in 2020 for $63B, adding Botox (aesthetics, neurotoxin therapeutics), Linzess, Vraylar, and other specialty pharmaceutical brands. | Johnson & Johnson post-Kenvue spinoff focuses on pharmaceuticals (Janssen) and medical devices (DePuy Synthes, Abiomed, surgical robotics). J&J's pharma portfolio is led by Darzalex (multiple myeloma), Stelara (psoriasis/Crohn's), Erleada (prostate cancer), and Tremfya (psoriasis). The medical devices division provides orthopedic implants, cardiac devices, and surgical tools. J&J's Janssen division competes directly with AbbVie in immunology — Tremfya (IL-23 inhibitor) competes with AbbVie's Skyrizi in psoriasis. J&J is a Dividend King with 60+ years of consecutive dividend increases. |
| Investor focus | Investors focus on Skyrizi and Rinvoq combined peak sales potential (expected to exceed Humira's peak), Botox aesthetics recovery, AbbVie's oncology and neuroscience pipeline, and Humira biosimilar impact management. | Investors focus on Darzalex growth and patent life, Stelara biosimilar impact (significant revenue loss underway), new drug launches (Rybrevant + lazertinib, nipocalimab), and talc litigation resolution. |
- Skyrizi and Rinvoq replacing Humira: Skyrizi (risankizumab) and Rinvoq (upadacitinib) are approved across multiple immunology indications and are on trajectory to collectively exceed Humira's $20B peak sales by 2027
- Botox franchise: Botox is a unique franchise in both aesthetics (wrinkle reduction) and therapeutic neurotoxin (chronic migraine, cervical dystonia, overactive bladder) — a deeply defensible brand with decades of safety and efficacy data
- Strong dividend: AbbVie is a Dividend Aristocrat with 50+ consecutive years of dividend increases (including Abbott's history) — paying approximately 4% yield with strong FCF coverage
- Darzalex global oncology dominance: Darzalex leads multiple myeloma treatment globally with continued label expansion and combination regimen adoption
- Medical devices providing non-pharma diversification: DePuy Synthes (orthopedic implants), Abiomed (ventricular assist devices), and surgical robotics provide revenue diversification beyond pharmaceutical pipeline risk
- Dividend King with 60+ year increase streak: J&J's 60+ consecutive annual dividend increases make it one of the most reliable income growth stocks in healthcare
- Humira biosimilar revenue decline: Humira US revenue is declining sharply as biosimilars capture market share — AbbVie must execute Skyrizi and Rinvoq growth to offset the $10B+ US Humira revenue decline
- Allergan acquisition debt: the $63B Allergan acquisition added significant debt — high leverage limits M&A flexibility while Humira revenues are declining
- JAK inhibitor safety label expansion risk: Rinvoq (JAK inhibitor) carries FDA warnings for serious infection, malignancy, and cardiovascular risk — expanding indications faces safety scrutiny that could limit label growth
- Stelara biosimilar revenue impact: Stelara generates $9B+ annually but faces US biosimilar competition after patent expiry in 2023 — significant revenue headwind requiring new launches to offset
- Talc litigation uncertainty: J&J's legal strategy to address talc litigation through subsidiary bankruptcy has faced court challenges — ongoing legal uncertainty creates financial overhang
- Immunology competition from AbbVie Skyrizi: Tremfya competes with Skyrizi in psoriasis — AbbVie's immunology pipeline is broader and deeper in indications vs J&J's Janssen immunology
Compare more than two at a time
This page is a fixed writeup on ABBV and JNJ. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside ABBV and JNJ, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.